URGN UROGEN PHARMA LTD revenue, earnings and financials
For the quarter ended June 30, 2026, UROGEN PHARMA LTD reported revenue of $72.5M (up 199.2% from a year earlier), net income of −$14.4M and diluted EPS of n/a; over the last four quarters revenue was $189M and net income −$97.6M; for the fiscal year ended December 2025 revenue was $110M, up 21.4% on the year before.
URGN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $110M, gross profit $97.3M, operating income −$125M, net income −$153M (margin -139.8%), EPS n/a
- Fiscal year ended Dec 2024: revenue $90.4M, gross profit $81.5M, operating income −$96.8M, net income −$127M (margin -140.4%), EPS n/a
- Fiscal year ended Dec 2023: revenue $82.7M, gross profit $73.4M, operating income −$65.5M, net income −$102M (margin -123.6%), EPS n/a
- Fiscal year ended Dec 2022: revenue $64.4M, gross profit $56.7M, operating income −$79.0M, net income −$110M (margin -170.6%), EPS n/a
- Fiscal year ended Dec 2021: revenue $48.0M, gross profit $42.9M, operating income −$92.3M, net income −$111M (margin -230.7%), EPS −$4.96
URGN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $72.5M (up 199.2% year over year), net income −$14.4M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $51.0M (up 151.6% year over year), net income −$23.6M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $37.8M (up 54.0% year over year), net income −$26.4M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $27.5M (up 9.0% year over year), net income −$33.3M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $24.2M (up 10.8% year over year), net income −$49.9M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $20.3M (up 7.8% year over year), net income −$43.8M, EPS n/a
- Quarter ended Dec 31, 2024: revenue $24.6M (up 4.4% year over year), net income −$37.5M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $25.2M (up 20.9% year over year), net income −$23.7M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $21.8M (up 3.4% year over year), net income −$33.4M, EPS n/a
- Quarter ended Mar 31, 2024: revenue $18.8M (up 9.2% year over year), net income −$32.3M, EPS n/a
- Quarter ended Dec 31, 2023: revenue $23.5M (up 30.1% year over year), net income −$26.0M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $20.9M (up 29.5% year over year), net income −$21.9M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $21.1M (up 27.3% year over year), net income −$24.1M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $17.2M (up 26.7% year over year), net income −$30.2M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $18.1M (up 11.9% year over year), net income −$28.9M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $16.1M (up 41.8% year over year), net income −$25.8M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $16.6M (up 27.4% year over year), net income −$26.7M, EPS n/a
- Quarter ended Mar 31, 2022: revenue $13.6M (up 81.2% year over year), net income −$28.4M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue $16.2M, net income −$28.5M, EPS −$1.27
- Quarter ended Sep 30, 2021: revenue $11.4M, net income −$30.2M, EPS −$1.35
URGN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$162M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$96.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$76.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$87.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$84.9M, share buybacks n/a
URGN balance sheet
- Jun 30, 2026: cash $79.1M, total assets $253M, total liabilities $385M, shareholders' equity −$132M, long-term debt $189M
- Mar 31, 2026: cash $110M, total assets $254M, total liabilities $378M, shareholders' equity −$124M, long-term debt $190M
- Dec 31, 2025: cash $111M, total assets $200M, total liabilities $306M, shareholders' equity −$105M, long-term debt $122M
- Sep 30, 2025: cash $90.0M, total assets $185M, total liabilities $300M, shareholders' equity −$115M, long-term debt $122M
- Jun 30, 2025: cash $92.9M, total assets $209M, total liabilities $302M, shareholders' equity −$93.4M, long-term debt $123M
- Mar 31, 2025: cash $104M, total assets $248M, total liabilities $294M, shareholders' equity −$46.5M, long-term debt $122M
- Dec 31, 2024: cash $172M, total assets $286M, total liabilities $295M, shareholders' equity −$8.80M, long-term debt $122M
- Sep 30, 2024: cash $125M, total assets $302M, total liabilities $276M, shareholders' equity $25.5M, long-term debt $122M
What is URGN's revenue?
UROGEN PHARMA LTD reported $189M of revenue over its last four quarters, through June 30, 2026.
Is URGN profitable?
No. UROGEN PHARMA LTD lost $97.6M over the last four quarters.